Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report
Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report
复制标题
一名 26 岁男性使用替莫唑胺后患急性淋巴细胞白血病：病例报告
DOI：
--
复制
发表时间：
2010
影响因子：
1
通讯作者：
N. Masood
中科院分区：
文献类型：
--
作者：
A. Shaikh;N. Masood
我们报告了一例使用替莫唑胺治疗脑肿瘤的患者发生急性淋巴细胞白血病的情况。与其他烷基化药物不同的是，替莫唑胺的致白血病潜力很低，这种情况很少被报道。病例介绍一名26岁的巴基斯坦男子，在辅助环境下使用替莫唑胺治疗胶质母细胞瘤，停用替莫唑胺一年后被诊断为急性淋巴细胞白血病。结论替莫唑胺是一种高度有效的药物，用于治疗高级别脑肿瘤。该制剂通常被认为是安全的，具有可接受的安全概况。很少有与替莫唑胺使用相关的骨髓发育不良的病例被报道。我们在这里报告第一例急性淋巴细胞白血病，发生在一名年轻男子结束服用替莫唑胺约一年后。这应该为进一步了解这种烷基化试剂可能的毒性提供了依据。这一发现应该引起一般内科医生的兴趣，尤其是内科肿瘤学家。
IntroductionWe report the development of acute lymphoblastic leukemia in a patient in whom temozolomide was used for the treatment of a brain tumor. Unlike that of other alkylating agents, the leukemogenic potential of temozolomide is considered to be very low, and very rarely are such cases reported.Case PresentationA 26-year-old Pakistani man who was treated for glioblastoma with temozolomide in an adjuvant setting was diagnosed to have acute lymphoblastic leukemia one year after stopping temozolomide.ConclusionTemozolomide is a highly active agent, used in the management of high-grade brain neoplasms. The agent is generally regarded to be safe, with an acceptable safety profile. Very few cases of myelodysplasia associated with temozolomide use have been reported. We report here the first case of acute lymphoblastic leukemia, which developed in a young man about one year after he finished taking temozolomide. This should provide further insight into a possible toxicity profile of this alkylating agent. This finding should be of interest to physicians in general and to medical oncologists in particular.